Teladoc Health (NYSE:TDOC) Shares Gap Up After Analyst Upgrade

Key Points

• Deutsche Bank upgrade to a "buy" (from "hold") with an $11 price target sent TDOC gapping up pre-market (opened $6.01 vs prior close $5.30).
• Teladoc beat Q4 estimates (EPS of ($0.14) vs. ($0.19) expected; revenue $642.27M) but remains unprofitable and issued negative Q1 and FY2026 EPS guidance (-0.45 to -0.35 Q1; -1.10 to -0.70 FY).
• Market sentiment remains mixed: MarketBeat shows a consensus "Hold" with an average price target of $7.76 (6 Buy / 13 Hold / 1 Sell), institutional investors own ~76.8% of shares, and insiders own 0.58% after the CEO sold shares.

Teladoc Health, Inc. (NYSE:TDOC - Get Free Report) gapped up before the market opened on Tuesday after Deutsche Bank Aktiengesellschaft upgraded the stock from a hold rating to a buy rating. The stock had previously closed at $5.30, but opened at $6.01. Deutsche Bank Aktiengesellschaft now has a $11.00 price target on the stock. Teladoc Health shares last traded at $5.5870, with a volume of 4,264,206 shares.

TDOC has been the subject of several other research reports. Stifel Nicolaus lowered their price target on Teladoc Health from $8.00 to $6.00 and set a "hold" rating for the company in a research note on Thursday, February 26th. Citigroup decreased their price objective on shares of Teladoc Health from $9.00 to $6.00 and set a "neutral" rating for the company in a report on Tuesday, March 3rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of Teladoc Health in a report on Monday, December 29th. Zacks Research lowered Teladoc Health from a "strong-buy" rating to a "hold" rating in a report on Monday, November 10th. Finally, Wells Fargo & Company dropped their target price on Teladoc Health from $8.00 to $6.00 and set an "equal weight" rating for the company in a report on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $7.76.

Insiders Place Their Bets

In other Teladoc Health news, CEO Charles Divita III sold 17,138 shares of the business's stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the transaction, the chief executive officer directly owned 201,036 shares of the company's stock, valued at approximately $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.58% of the company's stock.

Institutional Trading of Teladoc Health

A number of hedge funds and other institutional investors have recently modified their holdings of TDOC. Corient Private Wealth LLC grew its position in shares of Teladoc Health by 236.6% during the 4th quarter. Corient Private Wealth LLC now owns 37,692 shares of the health services provider's stock worth $264,000 after buying an additional 26,494 shares during the period. Alpine Global Management LLC acquired a new position in Teladoc Health in the fourth quarter valued at approximately $187,000. Virtu Financial LLC bought a new position in Teladoc Health in the fourth quarter valued at approximately $854,000. Mackenzie Financial Corp raised its position in shares of Teladoc Health by 38.6% during the 4th quarter. Mackenzie Financial Corp now owns 165,550 shares of the health services provider's stock valued at $1,157,000 after acquiring an additional 46,090 shares during the last quarter. Finally, Empowered Funds LLC lifted its stake in shares of Teladoc Health by 1.9% in the 4th quarter. Empowered Funds LLC now owns 742,305 shares of the health services provider's stock valued at $5,196,000 after purchasing an additional 14,029 shares during the period. Institutional investors and hedge funds own 76.82% of the company's stock.

Teladoc Health Price Performance

The company has a 50-day moving average price of $5.75 and a 200-day moving average price of $7.11. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.67 and a current ratio of 2.77. The firm has a market capitalization of $991.01 million, a P/E ratio of -4.87 and a beta of 2.13.

Teladoc Health (NYSE:TDOC - Get Free Report) last posted its earnings results on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The company had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. During the same period in the previous year, the company earned ($0.28) EPS. The company's revenue for the quarter was up .3% compared to the same quarter last year. Teladoc Health has set its Q1 2026 guidance at -0.450--0.350 EPS and its FY 2026 guidance at -1.100--0.700 EPS. On average, sell-side analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current year.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc's service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.